RNF144B
E3 ubiquitin-protein ligase RNF144B
Protein Summary
E3 ubiquitin-protein ligase which accepts ubiquitin from E2 ubiquitin-conjugating enzymes UBE2L3 and UBE2L6 in the form of a thioester and then directly transfers the ubiquitin to targeted substrates such as LCMT2, thereby promoting their degradation. Induces apoptosis via a p53/TP53-dependent but caspase-independent mechanism. However, its overexpression also produces a decrease of the ubiquitin-dependent stability of BAX, a pro-apoptotic protein, ultimately leading to protection of cell death; But, it is not an anti-apoptotic protein per se.
- ENST00000259939
- ENSP00000259939
- ENSG00000137393
- IBRDC2
- P53RFP
- PIR2
- IBRDC2
- p53RFP
- bA528A10.3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 0.88 | ||
microRNA | 0.74 | ||
transcription factor | 0.68 | ||
transcription factor binding site profile | 0.66 | ||
histone modification site profile | 0.6 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 49.54 (req: < 5)
Gene RIFs: 10 (req: <= 3)
Antibodies: 349 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 49.54 (req: >= 5)
Gene RIFs: 10 (req: > 3)
Antibodies: 349 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0